Steven L Batki
Overview
Explore the profile of Steven L Batki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
841
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luk J, Ha N, Shui A, Snyder H, Batki S, Ostacher M, et al.
Alcohol Clin Exp Res (Hoboken)
. 2024 Dec;
49(1):244-255.
PMID: 39632077
Background: Alcohol use disorder (AUD) treatment can help improve clinical outcomes among patients with alcohol-associated cirrhosis but is underutilized. Among socioeconomically disadvantaged patients with alcohol-associated cirrhosis, we examined rates of...
2.
Satre D, Dasarathy D, Batki S, Ostacher M, Snyder H, Hua W, et al.
Aliment Pharmacol Ther
. 2024 Nov;
61(3):481-490.
PMID: 39523996
Background And Aims: Alcohol use is prevalent among hepatology clinic patients with chronic liver disease (CLD). We explored factors associated with the importance and confidence dimensions of motivation to reduce...
3.
Athavale P, Wong R, Satre D, Monto A, Cheung R, Chen J, et al.
Gastro Hep Adv
. 2024 Aug;
3(2):201-209.
PMID: 39129958
Background And Aims: Telehealth has emerged as an important mode of cirrhosis care delivery, but its use and satisfaction among vulnerable populations (eg, racial/ethnic minorities, socioeconomically disadvantaged, substance use disorders)...
4.
Luk J, Satre D, Cheung R, Wong R, Monto A, Chen J, et al.
Hepatol Commun
. 2024 Feb;
8(2).
PMID: 38315141
Background: Management of cirrhosis is challenging and has been complicated by the COVID-19 pandemic due to decreased access to care, increased psychological distress, and alcohol misuse. Recently, The National Institute...
5.
Herbst E, Pennington D, Borsari B, Manuel J, Yalch M, Alcid E, et al.
Contemp Clin Trials
. 2023 Jun;
131:107250.
PMID: 37271412
Background: Tobacco and cannabis co-use is a growing public health problem. The synergistic effects of cannabis and nicotine on neurobiological systems that mediate reward and shared environmental cues reinforcing use...
6.
Baxley C, Borsari B, Reavis J, Manuel J, Herbst E, Becker W, et al.
Addict Behav
. 2022 Dec;
139:107589.
PMID: 36565531
Background: Craving is a distressing symptom of opioid use disorder (OUD) that can be alleviated with medications for OUD (MOUD). Buprenorphine is an effective MOUD that may suppress craving; however,...
7.
Hua J, Cano M, Batki S, Pennington D
Mil Med
. 2022 Sep;
188(7-8):e2208-e2216.
PMID: 36179109
Introduction: Alcohol use disorder (AUD) and PTSD have high rates of co-occurrence in U.S. Military Veterans resulting in incrementally worse functional outcomes relative to having either one of these disorders...
8.
Oslin D, Lynch K, Shih M, Ingram E, Wray L, Chapman S, et al.
JAMA
. 2022 Jul;
328(2):151-161.
PMID: 35819423
Importance: Selecting effective antidepressants for the treatment of major depressive disorder (MDD) is an imprecise practice, with remission rates of about 30% at the initial treatment. Objective: To determine whether...
9.
Pennington D, Reavis J, Cano M, Walker E, Batki S
Front Behav Neurosci
. 2022 Apr;
16:802711.
PMID: 35391785
Clinical Trial Registration: www.ClinicalTrials.gov, Identifier: NCT03786276.
10.
Stauffer C, Samson S, Hickok A, Hoffman W, Batki S
Front Psychiatry
. 2022 Feb;
12:804997.
PMID: 35111090
The increasing prevalence of illicit stimulant use among those in opioid treatment programs poses a significant risk to public health, stimulant users have the lowest rate of retention and poorest...